To our knowledge, this is the first case of SLMNs and undifferentiated sarcoma after treatment of ovarian mucinous cystadenocarcinoma of the ovary with KRAS, TP53, MLL2 and NF1 mutation. This evidence concerns the gene NF1 and undifferentiated (embryonal) sarcoma.